Life Tech Inks Companion Dx Alliance with Merck Serono | GenomeWeb

NEW YORK (GenomeWeb News) – Life Technologies today said that it has inked a companion diagnostics deal with pharmaceutical firm Merck Serono for an undisclosed oncology target and eventually other therapeutic areas.

Under the non-exclusive agreement, Life Tech will employ a wide range of its technology platforms, including next-generation sequencing, Sanger sequencing, qPCR, and flow cytometry. Life Tech said that it the alliance is successful, the firms would sign another agreement, under which the firm would commercialize the companion diagnostics in agreed-upon territories.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.